Details of the Drug

General Information of Drug (ID: DMCSLZ4)

Drug Name
Sodium zirconium cyclosilicate
Synonyms UZSi 9; ZS-9 compound; Sodium zirconium silicate (Na2ZrSi3O9); UZSi-9; CBTCHTJSGLCFMY-UHFFFAOYSA-N; 543686-27-7
Indication
Disease Entry ICD 11 Status REF
Hyperkalemia 5C76 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
V03AE10: Sodium zirconium cyclosilicate
V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A: ALL OTHER THERAPEUTIC PRODUCTS
V03: ALL OTHER THERAPEUTIC PRODUCTS
V: VARIOUS
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
1		 Molecular Weight 371.5
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 6
Hydrogen Bond Acceptor Count 9
Chemical Identifiers
Formula
H6Na2O9Si3Zr+2
IUPAC Name
disodium;2,2,4,4,6,6-hexahydroxy-1,3,5,2,4,6-trioxatrisilinane;zirconium
Canonical SMILES
O[Si]1(O[Si](O[Si](O1)(O)O)(O)O)O.[Na+].[Na+].[Zr]
InChI
InChI=1S/2Na.H6O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/h;;1-6H;/q2*+1;;
InChIKey
CBTCHTJSGLCFMY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
91799284
CAS Number
17141-74-1
UNII
D652ZWF066
DrugBank ID
DB14048
TTD ID
D03AZK

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium (K) TTB0SC6 NOUNIPROTAC Binder [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.